跳至主要内容
临床试验/NCT07174622
NCT07174622招募中不适用

Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data

Medtronic Vascular1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2025年10月28日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
1
主要终点
Change in Office Systolic Blood Pressure (OSBP)

研究概览

简要总结

This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.

详细描述

The SPYRAL CARE study is an observational, non-interventional study of the Medicare population with uncontrolled hypertension treated with either the Symplicity RDN system plus standard of care (SOC) or with SOC alone. SOC reflects active management of hypertension. The study will evaluate real-world clinical outcomes by examining deidentified, longitudinal data from administrative health insurance claims linked with EHR. The primary objective is to assess the change in office systolic blood pressure at two years for patients treated with Symplicity RDN plus SOC compared to similar patients receiving SOC alone. The secondary objective is to describe major adverse cardiac events over a two-year period in both groups. The study analysis is subject to a central Institutional Review Board (IRB) review. However, individual hospitals are not engaged in research, and local IRB oversight is not necessary.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Enrolled in a Medicare plan
  • Diagnosis of uncontrolled hypertension
  • On a stable regimen of antihypertensive therapy

排除标准

  • A prior RDN procedure
  • Diagnosis of secondary hypertension
  • Any condition for which RDN is contraindicated

研究组 & 干预措施

Symplicity RDN + SOC

Medicare patients on a stable antihypertension medication regimen and received RDN with a Symplicity RDN system

干预措施: Renal Denervation (Symplicity Spyral™) (Device)

SOC

Medicare patients on a stable antihypertension medication regimen

结局指标

主要结局

Change in Office Systolic Blood Pressure (OSBP)

时间窗: 2 years

Change in OSBP at two years relative to baseline between matched treated and comparator cohorts.

次要结局

  • Time to Major Cardiovascular Event (MACE)(2 years)

研究者

发起方
Medtronic Vascular
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验